- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 -
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Seeking Alpha / 6 hours ago 1 Views
Seeking Alpha / 6 hours ago 1 Views
- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 -
Comments